...
首页> 外文期刊>BMC Pediatrics >Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Sch?nlein purpura patients: a retrospective analysis
【24h】

Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Sch?nlein purpura patients: a retrospective analysis

机译:Fecal CalProtectin作为胃肠道受累的标志性儿科肝病患者:Nlein Purpura患者:回顾性分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Henoch–Sch?nlein purpura is a type of systemic vasculitis found in children. Its prognosis is usually good; however, recurrence is relatively common. If the intestines are affected, severe complications could arise. Here, we investigated the value of fecal calprotectin in the early screening of Henoch–Sch?nlein purpura and as a useful factor for predicting gastrointestinal manifestations. We retrospectively reviewed the medical records of pediatric patients who were diagnosed with Henoch–Sch?nlein purpura and underwent fecal calprotectin testing during the acute phase. The patients were categorized into gastrointestinal involvement and non-gastrointestinal involvement groups based on their clinical symptoms. Moreover, gastrointestinal involvement was categorized as follows: upper gastrointestinal tract involvement (up to the duodenum) and lower gastrointestinal tract involvement (from the terminal ileum). A total of 69 patients were diagnosed with Henoch–Sch?nlein purpura and underwent fecal calprotectin testing. Among them, 40 patients (58.0%) showed signs of gastrointestinal involvement. The gastrointestinal involvement group had higher fecal calprotectin levels (379.9?±?399.8 vs. 77.4?±?97.6?mg/kg, P?=?0.000). There were no significant differences in the recurrence of Henoch–Sch?nlein purpura symptoms or gastrointestinal symptoms. The cut-off value to identify gastrointestinal involvement was 69.10?mg/kg (P??0.01). Patients with fecal calprotectin levels of ?50?mg/kg showed more frequent gastrointestinal involvement (77.8% vs. 20.8%, P?=?0.000) and more severe gastrointestinal symptoms. Significant differences in abdominal pain duration, Henoch–Sch?nlein purpura clinical score, and abdominal pain severity were observed (P?=?0.002, P?=?0.000, and P?=?0.000, respectively). Additionally, fecal calprotectin levels were significantly higher in patients with lower gastrointestinal tract involvement (214.67?±?150.5 vs. 581.8?±?510.1?mg/kg, P?=?0.008), and the cut-off value was 277.5?mg/kg (P??0.01). Fecal calprotectin testing is useful for identifying gastrointestinal involvement in pediatric Henoch–Sch?nlein purpura patients.
机译:henoch-sch?nlein purpura是一种在儿童中发现的全身血管炎。其预后通常很好;然而,复发相对普遍。如果肠子受到影响,可能会出现严重的并发症。在这里,我们研究了粪便CalProtectin在Henoch-SCH的早期筛查中的价值,作为预测胃肠表现的有用因素。我们回顾性地审查了患有Henoch-SCH的儿科患者的病程,并在急性期间接受了粪便钙抗蛋白测试。根据其临床症状,患者分为胃肠道受累和非胃肠道受累群体。此外,胃肠道受累如下:上胃肠道受累(直至十二指肠)和低胃肠道受累(来自终端回肠)。共有69名患者被诊断出HELIN PURPURA并进行粪便酸素测试。其中,40名患者(58.0%)表现出胃肠道受累的迹象。胃肠道受累组具有较高的粪便冲击蛋白水平(379.9?±399.8与77.4?±97.6?mg / kg,p?= 0.000)。 Henoch-SCH的复发性没有显着差异症状或胃肠道症状。判断胃肠道受累的截止值为69.10?mg / kg(p?<?0.01)。患有粪便冲击蛋白水平>αmg/ kg的患者显示出更频繁的胃肠道受累(77.8%vs.2.8%,p?= 0.000)和更严重的胃肠道症状。观察到腹痛持续时间的显着差异,HELIN-SCH?NLEIN purpura临床评分,以及腹痛严重程度(p?= 0.002,p?= 0.000和p?=?0.000)。此外,胃肠道涉及较低的患者的粪便酸菌蛋白水平显着较高(214.67?±150.5与581.8?±510.1?mg / kg,p?= 0.008),截止值为277.5?mg / kg(p?<?0.01)。粪便酸蛋白检测可用于鉴定胃肠道中的胃肠道患者有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号